DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening & Drug Repositioning Benchmarks

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 clinically approved and pharmacopeia-listed compounds, enabling rapid and reproducible high-throughput screening (HTS) and high-content screening (HCS) workflows. The library includes drugs with diverse, well-characterized mechanisms of action such as receptor agonists/antagonists, enzyme inhibitors, and ion channel modulators [APExBIO Product Page]. Each compound is supplied as a 10 mM DMSO solution, compatible with automated liquid handling and stable for up to 24 months at -80°C. Benchmark studies validate the library’s utility in drug repositioning and target identification, including the identification of SARS-CoV-2 main protease inhibitors in yeast-based high-throughput assays (Sigurdardóttir et al., 2024). The DiscoveryProbe™ FDA-approved Drug Library serves as a reference standard for translational research in oncology, neurodegenerative disease, and signal pathway regulation.

Biological Rationale

Drug discovery and repositioning demand access to annotated compound libraries with established pharmacokinetics and safety data. The DiscoveryProbe™ FDA-approved Drug Library was developed to address the need for systematic, high-coverage screening of clinically relevant molecules. Its curation spans compounds approved by regulatory agencies such as the U.S. FDA, EMA, HMA, CFDA, and PMDA, as well as those listed in recognized pharmacopeias [APExBIO]. This ensures maximal translational relevance and regulatory tractability. The library’s diversity supports both hypothesis-driven and unbiased screens across disease models, facilitating identification of novel pharmacological targets and pathways. In particular, its validated inclusion of proteasome inhibitors, kinase inhibitors, and metabolic modulators addresses key druggable classes in cancer, infectious disease, and neurodegeneration [Site Article]. Where previous compound libraries lacked clinical validation or breadth, the DiscoveryProbe™ FDA-approved Drug Library provides a robust, ready-to-screen resource that accelerates both mechanistic and translational studies.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library encompasses compounds targeting a wide spectrum of molecular mechanisms. These include:

• Receptor Agonists and Antagonists: e.g., beta-blockers, opioid receptor modulators.
• Enzyme Inhibitors: e.g., kinase inhibitors, proteasome inhibitors (bortezomib, delanzomib, ixazomib).
• Ion Channel Modulators: e.g., calcium channel blockers.
• Signal Pathway Regulators: e.g., mTOR inhibitors, phosphodiesterase inhibitors.

The inclusion of compounds like doxorubicin (topoisomerase II inhibitor), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor) exemplifies the coverage of both established and emerging therapeutic classes. Each compound is annotated with its primary mechanism of action, regulatory status, and known off-target effects. This structured approach enables precise mapping of pharmacological activity to disease-relevant pathways [Related Article]. The library’s format supports both single-agent and combinatorial screening designs, facilitating mechanistic validation and prioritization in translational pipelines.

Evidence & Benchmarks

• Robust yeast-based high-throughput screening with the DiscoveryProbe™ FDA-approved Drug Library identified eight inhibitors of SARS-CoV-2 main protease (MPro), including three boron-containing proteasome inhibitors previously validated only in silico (Sigurdardóttir et al., 2024).
• Cellular assays using this library consistently distinguish true target engagement from general cytotoxicity, outperforming traditional in vitro enzymatic screens in selectivity and hit confirmation (Sigurdardóttir et al., 2024).
• Compounds are provided as pre-dissolved 10 mM DMSO solutions, ensuring stability for 12 months at -20°C and 24 months at -80°C, with no significant loss of activity reported under recommended storage conditions (APExBIO).
• Validated in multiple independent platforms for high-content imaging and phenotypic screening, the library supports signal pathway interrogation in cancer and neurodegenerative disease models (Internal Article).
• Inter-assay coefficient of variation (CV) across replicate screens typically remains below 10% when using automated liquid handling with 96-well or deep well plates (Internal Article).

Compared to other commercially available libraries, the DiscoveryProbe™ FDA-approved Drug Library demonstrates superior regulatory annotation and mechanistic diversity, as detailed in recent translational research benchmarks [Contrast: This article extends previous strategic analyses by quantifying stability and benchmarking assay performance].

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is widely used in:

• Drug Repositioning Screening: Rapidly identifies new indications for existing drugs.
• Pharmacological Target Identification: Facilitates pathway mapping and validation in disease models.
• Cancer Research Drug Screening: Enables systematic evaluation of compounds in tumor cell line panels.
• Neurodegenerative Disease Drug Discovery: Supports phenotypic screening for pathway modulators.
• Signal Pathway Regulation: Interrogates diverse signaling cascades with annotated modulators.
• Enzyme Inhibitor Screening: Rapidly benchmarks compounds against kinases, proteases, and metabolic enzymes.

Limitations and context:

• The library is not optimized for de novo chemical diversity; it is focused on clinically validated molecules.
• It does not include investigational compounds or those lacking regulatory approval.
• Phenotypic screening may yield hits that require secondary validation for on-target effects.
• Compound solubility and DMSO tolerability must be considered in cell-based assays.

Common Pitfalls or Misconceptions

• Misconception: The library covers all possible druggable space. Fact: Only FDA/EMA/HMA/CFDA/PMDA-approved or pharmacopeia-listed compounds are included.
• Pitfall: Assuming all compounds are active under any assay buffer. Clarification: Activity may depend on buffer composition, as shown for boron-containing proteasome inhibitors in SARS-CoV-2 MPro assays (Sigurdardóttir et al., 2024).
• Misconception: Ready-to-screen format eliminates the need for QC. Fact: Researchers should confirm compound integrity before critical experiments.
• Pitfall: Interpreting cytotoxicity as target-specific inhibition. Clarification: Use appropriate secondary assays for specificity.
• Misconception: The library is suitable for primary in vivo screening. Fact: It is designed for in vitro HTS/HCS; in vivo use requires additional formulation and dosing validation.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is supplied as pre-dissolved 10 mM DMSO solutions in 96-well or deep well plates, and 2D barcoded screw-top tubes. Plates are compatible with standard robotic liquid handlers and high-content imaging platforms. Shipping conditions are tailored to sample size, with blue ice for evaluation kits and room temperature or blue ice for bulk orders. Upon receipt, compounds should be stored at -20°C for short-term use (≤12 months) or -80°C for long-term storage (≤24 months). Thawing cycles should be minimized to preserve compound integrity. Prior to screening, compounds can be diluted into assay buffer, ensuring DMSO concentrations do not exceed cell tolerance (typically ≤0.1–0.5% v/v). Integration with automated workflows enables inter-assay CVs below 10%, enhancing reproducibility. The library’s structure and annotation support direct import into cheminformatics and laboratory information management systems (LIMS). For further guidance on protocol optimization and strategic applications, see Strategic Horizons in Translational Discovery (this article extends previous discussion by detailing format stability and cold-chain logistics).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO represents a benchmark resource for high-throughput and high-content screening in drug discovery, repositioning, and mechanism-of-action studies. Its rigorous curation, robust stability, and comprehensive annotation enable translational researchers to rapidly identify actionable therapeutic targets and repurpose existing drugs across diverse biomedical domains. Recent benchmarks, such as the identification of new SARS-CoV-2 MPro inhibitors, underscore its value in both emergent and established disease models (Sigurdardóttir et al., 2024). While not a substitute for de novo compound libraries or in vivo validation, the DiscoveryProbe™ FDA-approved Drug Library provides an unparalleled starting point for rational drug discovery and rapid response to unmet clinical needs. For full specifications and ordering details, visit the DiscoveryProbe™ FDA-approved Drug Library product page. For additional perspectives on workflow integration, see related articles here (this article provides updated stability and benchmarking data) and here (this article focuses on curation and regulatory coverage).